Sidoti Brokers Increase Earnings Estimates for Cibus

Key Points

• Sidoti raised its Q1 2026 EPS estimate for Cibus to ($0.32) from ($0.36) and now projects FY2026 EPS of ($1.18) and FY2027 EPS of ($0.88), per analyst A. Hantman.
• Shares fell about 6.8% to $2.48 on the report; the company is a small-cap ($134.6M) that slightly beat Q1 EPS estimates ($0.42 vs. $0.43) but missed revenue ($1.06M vs. $1.64M) and reported extremely negative net margin and ROE.
• Institutional interest is rising: several hedge funds recently established or increased positions and institutions now own about 33.81% of the stock, while analyst consensus remains a "Hold" with an average target of $15.00.

Cibus, Inc. (NASDAQ:CBUS - Free Report) - Equities research analysts at Sidoti upped their Q1 2026 earnings estimates for shares of Cibus in a research note issued to investors on Thursday, March 19th. Sidoti analyst A. Hantman now forecasts that the company will earn ($0.32) per share for the quarter, up from their previous forecast of ($0.36). The consensus estimate for Cibus' current full-year earnings is ($2.96) per share. Sidoti also issued estimates for Cibus' Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.18) EPS, Q1 2027 earnings at ($0.21) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.23) EPS and FY2027 earnings at ($0.88) EPS.

A number of other brokerages have also weighed in on CBUS. Canaccord Genuity Group restated a "buy" rating and issued a $15.00 target price on shares of Cibus in a research note on Monday, December 8th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Cibus in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Cibus has an average rating of "Hold" and an average target price of $15.00.

Cibus Trading Down 6.8%

Shares of CBUS stock opened at $2.48 on Monday. The company has a market capitalization of $134.61 million, a PE ratio of -0.83 and a beta of 1.62. Cibus has a 52-week low of $1.09 and a 52-week high of $4.19. The business's fifty day moving average is $2.65 and its 200 day moving average is $1.91. The company has a debt-to-equity ratio of 1.37, a quick ratio of 0.72 and a current ratio of 0.72.

Cibus (NASDAQ:CBUS - Get Free Report) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.01. The firm had revenue of $1.06 million during the quarter, compared to analyst estimates of $1.64 million. Cibus had a negative net margin of 3,492.30% and a negative return on equity of 174.58%.

Institutional Trading of Cibus

Hedge funds have recently made changes to their positions in the stock. Gratia Capital LLC bought a new position in Cibus in the second quarter valued at $1,183,000. Prescott Group Capital Management L.L.C. bought a new stake in Cibus during the fourth quarter worth about $345,000. Jane Street Group LLC purchased a new position in shares of Cibus in the 2nd quarter worth about $207,000. Certior Financial Group LLC boosted its holdings in shares of Cibus by 46.7% in the 4th quarter. Certior Financial Group LLC now owns 271,164 shares of the company's stock worth $472,000 after purchasing an additional 86,378 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new position in shares of Cibus during the 4th quarter valued at about $145,000. 33.81% of the stock is owned by institutional investors.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company's platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company's core business centers on trait development services and licensing partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.